<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>License</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Frontier Medicine licenses FMC-220 ex-China rights to LG Chem</title>
      <description>
        <![CDATA[Frontier Medicines Corp. has granted LG Chem Ltd. an exclusive worldwide license to develop and commercialize FMC-220, a covalent p53 Y220C activator, outside of Greater China. Frontier retains ownership and full control in Greater China.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730097</guid>
      <pubDate>Thu, 02 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730097-frontier-medicine-licenses-fmc-220-ex-china-rights-to-lg-chem</link>
    </item>
    <item>
      <title>Kyorin licenses Ube drug candidates</title>
      <description>
        <![CDATA[Kyorin Pharmaceutical Co. Ltd. and Ube Corp. have entered into a license agreement for novel drug candidates discovered by Ube.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729791</guid>
      <pubDate>Mon, 23 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729791-kyorin-licenses-ube-drug-candidates</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/drug-development-research.webp?t=1618519686" type="image/png" medium="image" fileSize="696743">
        <media:title type="plain">Illustration of pill being analyzed</media:title>
      </media:content>
    </item>
    <item>
      <title>Counterx signs license supporting work in fentanyl overdose</title>
      <description>
        <![CDATA[Counterx Therapeutics Inc. has executed an exclusive licensing agreement with the University of Minnesota and the University of Washington for a portfolio of novel monoclonal antibody and vaccine candidates targeting fentanyl and opioid overdose.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729590</guid>
      <pubDate>Wed, 11 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729590-counterx-signs-license-supporting-work-in-fentanyl-overdose</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Misc/Substance-use-opioids-overdose.webp?t=1690469144" type="image/jpeg" medium="image" fileSize="278724">
        <media:title type="plain">Various pills and powders in small plastic ziplock bags</media:title>
      </media:content>
    </item>
    <item>
      <title>UCB and Antengene sign license agreement for ATG-201</title>
      <description>
        <![CDATA[UCB SA and Antengene Corp. Ltd. have entered into a license agreement that grants UCB a worldwide exclusive license to further develop, manufacture and commercialize ATG-201. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/729326</guid>
      <pubDate>Wed, 04 Mar 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729326-ucb-and-antengene-sign-license-agreement-for-atg-201</link>
    </item>
    <item>
      <title>Kairos Pharma to acquire Celyn’s pan-EGFR inhibitor</title>
      <description>
        <![CDATA[Kairos Pharma Ltd. has entered into binding terms to acquire CL-273 from Celyn Therapeutics Inc.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729132</guid>
      <pubDate>Mon, 02 Mar 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729132-kairos-pharma-to-acquire-celyns-pan-egfr-inhibitor</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Pill-over-molecule-structures.webp?t=1588352713" type="image/png" medium="image" fileSize="273700">
        <media:title type="plain">Pill over molecule structures</media:title>
      </media:content>
    </item>
    <item>
      <title>Boehringer Ingelheim licenses Sitryx small-molecule program</title>
      <description>
        <![CDATA[Boehringer Ingelheim Ltd. has acquired an exclusive license for a preclinical small-molecule program from Sitryx Therapeutics Ltd. The program offers a novel oral immunometabolic approach to modulating disease-driving immune cells with potential for multiple autoimmune and inflammatory disease indications.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729113</guid>
      <pubDate>Fri, 27 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729113-boehringer-ingelheim-licenses-sitryx-small-molecule-program</link>
    </item>
    <item>
      <title>GSK licenses Frontier Biotechnologies’ siRNA therapeutics </title>
      <description>
        <![CDATA[Frontier Biotechnologies Inc. has entered into an exclusive licensing agreement with GSK plc whereby GSK will obtain exclusive worldwide rights to develop, manufacture and commercialize two of Frontier’s small interfering RNA (siRNA) pipeline products.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729033</guid>
      <pubDate>Wed, 25 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729033-gsk-licenses-frontier-biotechnologies-sirna-therapeutics</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Nephrology/kidney-genetic-congenital.webp?t=1709655526" type="image/jpeg" medium="image" fileSize="168177">
        <media:title type="plain">Illustration of kidney with DNA structures</media:title>
      </media:content>
    </item>
    <item>
      <title>Angelini and Quiver Bioscience partner in genetic epilepsies</title>
      <description>
        <![CDATA[Angelini Pharma SpA and Quiver Bioscience Inc. have entered into a collaboration and licensing agreement to advance novel therapeutics for genetic epilepsies. Under the multiyear collaboration, Angelini Pharma will leverage Quiver’s technology platform to gain deeper understanding of a broad set of developmental and epileptic encephalopathies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729017</guid>
      <pubDate>Tue, 24 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729017-angelini-and-quiver-bioscience-partner-in-genetic-epilepsies</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Brain-and-DNA2.webp?t=1663611764" type="image/png" medium="image" fileSize="254381">
        <media:title type="plain">Brain and DNA </media:title>
      </media:content>
    </item>
    <item>
      <title>Apertura Gene Therapy signs FRRS1L license agreement </title>
      <description>
        <![CDATA[Nonprofit Finding Hope for Frizzle (FRRS1L) and Apertura Gene Therapy have signed a license agreement for the development of a gene therapy for FRRS1L disease, also known as early infantile epileptic encephalopathy type 37, using Apertura’s CNS-targeting TfR1 CapX AAV capsid.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728939</guid>
      <pubDate>Thu, 19 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728939-apertura-gene-therapy-signs-frrs1l-license-agreement</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Brain-and-DNA.webp?t=1616096016" type="image/png" medium="image" fileSize="453052">
        <media:title type="plain">Brain and DNA</media:title>
      </media:content>
    </item>
    <item>
      <title>Stoked Bio licenses rights to enterololin for Crohn’s disease</title>
      <description>
        <![CDATA[Stoked Bio Inc. has secured an exclusive global license from McMaster University for the patents covering enterololin, a promising narrow-spectrum antibiotic.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728937</guid>
      <pubDate>Thu, 19 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728937-stoked-bio-licenses-rights-to-enterololin-for-crohns-disease</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/NIH-NIAID-Scanning-electron-micrograph-of-Escherichia-coli.webp?t=1667837128" type="image/png" medium="image" fileSize="2031153">
        <media:title type="plain">Colorized scanning electron micrograph of E. coli bacteria.</media:title>
        <media:description type="plain">Escherichia coli bacteria. Credit: National Institute of Allergy and Infectious Diseases, NIH
</media:description>
      </media:content>
    </item>
    <item>
      <title>Asahi Kasei Pharma acquires rights to Alchemedicine compounds</title>
      <description>
        <![CDATA[Alchemedicine Inc. and Asahi Kasei Pharma Corp. have entered into an exclusive license agreement on lead HiSAP (high solubility and permeability) compounds owned by Alchemedicine. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/728901</guid>
      <pubDate>Tue, 17 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728901-asahi-kasei-pharma-acquires-rights-to-alchemedicine-compounds</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Research-deal-collaboration-handshake.webp?t=1742309543" type="image/jpeg" medium="image" fileSize="227377">
        <media:title type="plain">Scientists shaking hands in the lab</media:title>
      </media:content>
    </item>
    <item>
      <title>Nxera announces partner program updates</title>
      <description>
        <![CDATA[Nxera Pharma Co. Ltd. has announced the achievement of an early development milestone by Centessa Pharmaceuticals plc for ORX-489, triggering a payment to Nxera under the companies’ research collaboration.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728830</guid>
      <pubDate>Fri, 13 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728830-nxera-announces-partner-program-updates</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Life-sciences.webp?t=1683033198" type="image/jpeg" medium="image" fileSize="291424">
        <media:title type="plain">Lab glassware and scientist</media:title>
      </media:content>
    </item>
    <item>
      <title>Madrigal licenses six Ribo siRNA programs</title>
      <description>
        <![CDATA[Madrigal Pharmaceuticals Inc. has signed an exclusive global license agreement with Suzhou Ribo Life Science Co. Ltd. and its subsidiary Ribocure Pharmaceuticals AB for six preclinical small interfering RNA (siRNA) programs.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728784</guid>
      <pubDate>Wed, 11 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728784-madrigal-licenses-six-ribo-sirna-programs</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/siRNA.webp?t=1590081687" type="image/png" medium="image" fileSize="147005">
        <media:title type="plain">siRNA bound to mRNA</media:title>
      </media:content>
    </item>
    <item>
      <title>Biodexa licenses Otsuka’s molecular glue OPB-171775 for GIST</title>
      <description>
        <![CDATA[Biodexa Pharmaceuticals plc has closed an exclusive license agreement with Otsuka Pharmaceutical Co. Ltd. for OPB-171775 (now MTX-240), a phase I-ready molecular glue intended to be developed for the treatment of gastrointestinal stromal tumors (GIST) and potentially additional indications.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728628</guid>
      <pubDate>Thu, 05 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728628-biodexa-licenses-otsukas-molecular-glue-opb-171775-for-gist</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/molecular-glue-protein-interaction.webp?t=1751899039" type="image/jpeg" medium="image" fileSize="475550">
        <media:title type="plain">3D rendering of a molecular glue mediating the interaction between two proteins</media:title>
      </media:content>
    </item>
    <item>
      <title>Meiragtx licenses Zipbio’s gene therapies for geographic atrophy</title>
      <description>
        <![CDATA[Zipbio has signed an exclusive license agreement with Meiragtx Holdings plc to advance an AAV gene therapy for geographic atrophy. Under the agreement, Meiragtx will receive exclusive rights to Zipbio’s first-in-class therapies targeting the complement pathway for geographic atrophy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728602</guid>
      <pubDate>Wed, 04 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728602-meiragtx-licenses-zipbios-gene-therapies-for-geographic-atrophy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Eya-and-DNA-illustration.webp?t=1658513444" type="image/png" medium="image" fileSize="350713">
        <media:title type="plain">Eye and DNA illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Advancell and 48Hour Discovery partner on 212Pb radiotherapeutic</title>
      <description>
        <![CDATA[Advancell Pty Ltd. has entered into a collaboration and exclusive licensing agreement with 48Hour Discovery Inc. to develop a novel peptide-based lead-212 (212Pb) radiotherapeutic with an initial focus on a gastrointestinal cancer with significant medical need.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728512</guid>
      <pubDate>Tue, 03 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728512-advancell-and-48hour-discovery-partner-on-212pb-radiotherapeutic</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Radiotherapy-of-cancer.webp?t=1666626496" type="image/png" medium="image" fileSize="567967">
        <media:title type="plain">Radiotherapy of cancer </media:title>
      </media:content>
    </item>
    <item>
      <title>Kahimmune Therapeutics signs licensing agreement</title>
      <description>
        <![CDATA[Kahimmune Therapeutics SAS has signed an exclusive licensing agreement with Gustave Roussy and SATT Paris-Saclay. Created at the end of last year as a spin-off of Gustave Roussy and SATT Paris-Saclay, Kahimmune builds on the latest discoveries in immunology relating to the dark genome.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728510</guid>
      <pubDate>Tue, 03 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728510-kahimmune-therapeutics-signs-licensing-agreement</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Deal-illustration1.webp?t=1613684293" type="image/png" medium="image" fileSize="542426">
        <media:title type="plain">Handshake with DNA, molecules</media:title>
      </media:content>
    </item>
    <item>
      <title>Formation Bio in-licenses miR-124 activator</title>
      <description>
        <![CDATA[Formation Bio Inc. and Jiangsu Chia Tai Feng Hai Pharmaceutical Co. Ltd. have announced Formation Bio’s acquisition of worldwide rights, excluding Greater China, to FHND-5032, an oral, small-molecule miR-124 activator being developed for the treatment of autoimmune diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728435</guid>
      <pubDate>Fri, 30 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728435-formation-bio-in-licenses-mir-124-activator</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/microRNA-or-miRNA.webp?t=1769784078" type="image/jpeg" medium="image" fileSize="237409">
        <media:title type="plain">microRNA or miRNA</media:title>
      </media:content>
    </item>
    <item>
      <title>Boehringer Ingelheim and Simcere partner on SIM-0709</title>
      <description>
        <![CDATA[Boehringer Ingelheim International GmbH and Simcere Pharmaceutical Group Ltd. have entered into a license and collaboration agreement to develop SIM-0709 for the treatment of inflammatory bowel disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728375</guid>
      <pubDate>Tue, 27 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728375-boehringer-ingelheim-and-simcere-partner-on-sim-0709</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/global-business-trade-deal.webp?t=1588276966" type="image/png" medium="image" fileSize="2119366">
        <media:title type="plain">Handshake with digital globe overlay</media:title>
      </media:content>
    </item>
    <item>
      <title>Insilico Medicine and Hygtia partner on ISM-8969</title>
      <description>
        <![CDATA[Insilico Medicine Cayman Topco and Hygtia Therapeutics Co. Ltd. have entered into an exclusive license and co-development collaboration to advance ISM-8969 worldwide. ISM-8969 is an orally available, brain penetrant NLRP3 inhibitor for CNS disorders.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728186</guid>
      <pubDate>Wed, 21 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728186-insilico-medicine-and-hygtia-partner-on-ism-8969</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Brain-as-filament-in-light-bulb.webp?t=1695304772" type="image/jpeg" medium="image" fileSize="168302">
        <media:title type="plain">Brain as light bulb filament</media:title>
      </media:content>
    </item>
    <item>
      <title>Smartbax in-licenses antibacterials from Aicuris</title>
      <description>
        <![CDATA[Smartbax GmbH has in-licensed a new compound class from the antibacterial portfolio of Aicuris Anti-infective Cures AG to expand its proprietary pipeline of small-molecule antibiotics.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728113</guid>
      <pubDate>Tue, 20 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728113-smartbax-in-licenses-antibacterials-from-aicuris</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/NIH-NIGMS-E-coli.webp?t=1683731618" type="image/png" medium="image" fileSize="1739081">
        <media:title type="plain">Electron microscopy of E. coli bacteria.</media:title>
        <media:description type="plain">Escherichia coli bacteria. Credit: Mark Ellisman and Thomas Deerinck, National Center for Microscopy and Imaging Research/University of California, San Diego/NIH
</media:description>
      </media:content>
    </item>
    <item>
      <title>Henlius in-licenses anti-IL-1RAP antibody from U-mab Biopharma</title>
      <description>
        <![CDATA[Shanghai Henlius Biotech Inc. has entered into an exclusive global license agreement with U-mab Biopharma (Lianyungang) Co. Ltd., securing rights to a monoclonal antibody (mAb) targeting interleukin-1 receptor accessory protein (IL-1RAP) for inflammatory and autoimmune diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727991</guid>
      <pubDate>Thu, 15 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727991-henlius-in-licenses-anti-il-1rap-antibody-from-u-mab-biopharma</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Antibody-pic.webp?t=1588349803" type="image/png" medium="image" fileSize="392531">
        <media:title type="plain">Antibody</media:title>
      </media:content>
    </item>
    <item>
      <title>Généthon and Askbio enter Pompe licensing agreement</title>
      <description>
        <![CDATA[Généthon, a nonprofit laboratory created by the AFM-Téléthon, has reported its exclusive, worldwide licensing agreement with Askbio Inc., a subsidiary of Bayer AG, for the use of a patented component of AB-1009, under development by Askbio, for the treatment of Pompe disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727956</guid>
      <pubDate>Wed, 14 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727956-genethon-and-askbio-enter-pompe-licensing-agreement</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Gene-therapy-adeno-associated-virus-AAV.webp?t=1669825128" type="image/png" medium="image" fileSize="1419974">
        <media:title type="plain">Concept art for adeno-associated viral-based gene therapy.</media:title>
      </media:content>
    </item>
    <item>
      <title>Hyloris in-licenses European rights to Arbormed copper chelator</title>
      <description>
        <![CDATA[Hyloris Pharmaceuticals SA has entered into a license agreement with Arbormed Co. Ltd. for exclusive rights in Europe and Turkey to Arbormed’s novel injectable product candidate for Wilson’s disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727647</guid>
      <pubDate>Mon, 05 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727647-hyloris-in-licenses-european-rights-to-arbormed-copper-chelator</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Copper-atom-illustration.webp?t=1752176355" type="image/png" medium="image" fileSize="326529">
        <media:title type="plain">Copper atom illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Adlai Nortye licenses AN-9025 to Ask Pharm</title>
      <description>
        <![CDATA[Adlai Nortye Ltd. has entered into an exclusive licensing agreement with Jiangsu Aosaikang Pharmaceutical Co. Ltd. (Ask Pharm) for its proprietary pan-RAS(ON) inhibitor AN-9025, an oral small molecule designed to target a broad spectrum of RAS mutations across various tumor types.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727461</guid>
      <pubDate>Mon, 29 Dec 2025 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727461-adlai-nortye-licenses-an-9025-to-ask-pharm</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Deal-merger-money-lightbulb.webp?t=1588286368" type="image/png" medium="image" fileSize="65086">
        <media:title type="plain">Handshake, businessmen holding dollar sign, lightbulb</media:title>
      </media:content>
    </item>
    <item>
      <title>Ipsen licenses ex-China rights to Simcere Zaiming’s SIM-0613</title>
      <description>
        <![CDATA[Ipsen SA has signed an exclusive licensing agreement with Simcere Zaiming Pharmaceutical Co. Ltd. for global rights outside of Greater China for SIM-0613, an LRRC15-targeting antibody-drug conjugate developed by Simcere Zaiming for solid tumors. The program is expected to enter phase I development in the second half of next year.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727403</guid>
      <pubDate>Mon, 22 Dec 2025 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727403-ipsen-licenses-ex-china-rights-to-simcere-zaimings-sim-0613</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Antibody-drug-conjugates-ADCs-3D.webp?t=1751620465" type="image/jpeg" medium="image" fileSize="160333">
        <media:title type="plain">3D rendering of an antibody-drug conjugate</media:title>
      </media:content>
    </item>
    <item>
      <title>Tonix licenses S1R antagonist from Rutgers University</title>
      <description>
        <![CDATA[Tonix Pharmaceuticals Holding Corp. has licensed exclusive worldwide rights to TNX-4900 (formerly PW-507) from Rutgers University. TNX-4900 is a highly selective, small-molecule sigma-1 receptor (S1R) antagonist, which has demonstrated analgesic activity in multiple models of neuropathic pain.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727180</guid>
      <pubDate>Wed, 17 Dec 2025 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727180-tonix-licenses-s1r-antagonist-from-rutgers-university</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/pain-neuron-synapse.webp?t=1722265123" type="image/jpeg" medium="image" fileSize="239514">
        <media:title type="plain">Art concept for pain</media:title>
      </media:content>
    </item>
    <item>
      <title>Taigen in-licenses Insilico Medicine’s PHD inhibitor ISM-4808</title>
      <description>
        <![CDATA[Taigen Biotechnology Co. Ltd. and its Taigen Biopharmaceuticals subsidiary have entered into an exclusive in-licensing agreement with Insilico Medicine Inc. for ISM-4808, a prolyl hydroxylase domain (PHD) inhibitor.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727130</guid>
      <pubDate>Mon, 15 Dec 2025 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727130-taigen-in-licenses-insilico-medicines-phd-inhibitor-ism-4808</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/research-collaboration-deal-handshake-gloves.webp?t=1765812758" type="image/jpeg" medium="image" fileSize="419449">
        <media:title type="plain">Photo of researchers shaking hands</media:title>
      </media:content>
    </item>
    <item>
      <title>Toolgen and Geneditbio to advance genome-editing therapeutics</title>
      <description>
        <![CDATA[Toolgen Inc. has entered into a strategic cross-license agreement with Geneditbio Ltd. to jointly advance the development of next-generation in vivo genome-editing therapeutics.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726545</guid>
      <pubDate>Tue, 25 Nov 2025 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726545-toolgen-and-geneditbio-to-advance-genome-editing-therapeutics</link>
    </item>
    <item>
      <title>Mwyngil Therapeutics in-licenses GPR75 modulators</title>
      <description>
        <![CDATA[Mwyngil Therapeutics Inc. has in-licensed several lead GPR75 modulator molecules and a proprietary cell-surface discovery platform from Expert Systems Inc. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/725908</guid>
      <pubDate>Fri, 07 Nov 2025 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/725908-mwyngil-therapeutics-in-licenses-gpr75-modulators</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Diabetes/human-body-metabolism.webp?t=1726239536" type="image/jpeg" medium="image" fileSize="320060">
        <media:title type="plain">Art concept for metabolism</media:title>
      </media:content>
    </item>
  </channel>
</rss>
